Healthcare
HUTCHMED (China) Limited(HMDCF)
Live Price
Offline$2.16
+0.00% today
1Y Change
-32.61%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $2.32B
- Revenue Growth
- -12.8%
- EPS Growth
- +1101.8%
- Dividend Yield
- 0.0%
Coverage: 256 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
HUTCHMED (China) Limited (HMDCF) is a Healthcare stock with a market cap of $2.32B and listed on OTC. The stock last traded around $2.16 and down 32.6% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of -12.8%, EPS growth of +1101.8%, a dividend yield of 0.0%. What stands out right now is revenue -12.8%, EPS +1101.8%, free cash flow -352.6% with operating margin -2.6% and ROIC -0.7%. Valuation is more restrained than many high-expectation growth names at P/E 5.1 and price/sales 5.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HMDCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-12.8% vs +7.6% peer median
Operating Margin
Below sector median
-2.6% vs +19.4% peer median
P/E
Below sector median
5.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 17, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -12.8% and EPS is at +1101.8%, with operating margin around -2.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 3, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 17, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 5, 2026 | โ | +0.0% | -5.9% | -5.9% |
2025 Aug 7, 2025 | -10.5% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
HMDCF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HMDCF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HMDCF Max Drawdown
-40.98%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HMDCF and SPY.
Company Overview
HUTCHMED (China) Limited
Other OTC
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.
- Leadership
- Chig Fung Cheng
- IPO Date
- Apr 17, 2014
- Employees
- 1.8k
- Street Address
- Cheung Kong Center
- Mailing
- Hong Kong
- Region
- Hong Kong, HK
- Reporting Currency
- USD
- Investor Line
- 852 2128 1188
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 5.1
- EV/EBITDA
- โ
- Price/Sales
- 5.3
- Price/Book
- 1.9
Growth
- Revenue
- -12.8%
- EPS
- +1101.8%
- Free Cash Flow
- -352.6%
Profitability
- Gross Margin
- 18.6%
- Operating Margin
- -2.6%
- Net Margin
- 104.8%
- ROE
- 41.4%
- ROIC
- -0.7%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 4.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.